Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1

Vaddady Pavan; Kandala Bhargava; Yee Ka Lai

首页> 外文期刊>Antimicrobial agents and chemotherapy. >Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1

【24h】

Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1

机译：Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Doravirine is a non-nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus type 1 (HIV-1) infection. A population pharmacokinetic (PK) model for treatment-naive participants in doravirine clinical studies was updated with data from switch participants in the DRIVE-SHIFT trial and used to estimate individual post hoc PK parameter values and evaluate the efficacy exposure-response relationship. The results support the 100-mg dose for people living with HIV switching to a doravirine-based regimen.

著录项

来源
《Antimicrobial agents and chemotherapy.》 |2020年第11期|共5页
作者
Vaddady Pavan; Kandala Bhargava; Yee Ka Lai;
展开▼
作者单位

Merck & Co Inc, Kenilworth, NJ 07033 USA;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类治疗学;
关键词
doravirine; fixed-dose combination; non-nucleoside reverse transcriptase inhibitor; population pharmacokinetic model; switch treatment;

Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1

摘要

著录项

相关主题

期刊订阅